Blue Jet Healthcare Ltd
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
- Market Cap ₹ 7,250 Cr.
- Current Price ₹ 418
- High / Low ₹ 447 / 319
- Stock P/E 42.4
- Book Value ₹ 48.7
- Dividend Yield 0.00 %
- ROCE 30.0 %
- ROE 22.4 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.4%
Cons
- Stock is trading at 8.58 times its book value
- Working capital days have increased from 146 days to 213 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 538 | 499 | 683 | 721 | 712 | |
| 325 | 292 | 434 | 502 | 482 | |
| Operating Profit | 214 | 207 | 249 | 219 | 229 |
| OPM % | 40% | 41% | 36% | 30% | 32% |
| 6 | 9 | 19 | 24 | 19 | |
| Interest | 7 | 5 | 3 | 1 | 0 |
| Depreciation | 18 | 20 | 22 | 25 | 28 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 |
| Tax % | 25% | 26% | 25% | 26% | 26% |
| 145 | 142 | 182 | 160 | 164 | |
| EPS in Rs | 24,118.33 | 1,428.57 | 10.47 | 9.23 | 9.44 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 7% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 28% |
| Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 10 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 |
| 74 | 53 | 19 | 5 | 2 | |
| 92 | 143 | 173 | 176 | 212 | |
| Total Liabilities | 364 | 536 | 713 | 862 | 1,059 |
| 107 | 0 | 156 | 151 | 172 | |
| CWIP | 2 | 3 | 3 | 30 | 147 |
| Investments | 26 | 37 | 94 | 189 | 250 |
| 229 | 497 | 460 | 491 | 489 | |
| Total Assets | 364 | 536 | 713 | 862 | 1,059 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 122 | 137 | 146 | 142 | 241 | |
| -45 | -61 | -76 | -147 | -264 | |
| -72 | -21 | -56 | -4 | -2 | |
| Net Cash Flow | 5 | 55 | 14 | -10 | -24 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 |
| Inventory Days | 120 | 201 | 133 | 137 | 151 |
| Days Payable | 90 | 101 | 72 | 58 | 35 |
| Cash Conversion Cycle | 110 | 204 | 183 | 199 | 206 |
| Working Capital Days | 64 | 105 | 105 | 121 | 213 |
| ROCE % | 58% | 52% | 35% | 30% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Jul - Certificate under regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018for the quarter ended 30th June 2024 received from Linkintime India Pvt. Ltd., RTA of …
- Disclosure Under Regulation 30 Of The SEBI (LODR)- Commissioning Of Multi- Product Production Block At Ambernath [Unit II] 30 Jun
- Closure of Trading Window 26 Jun
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
31 May - Transcript of the Earnings Call with the Analysts/ Investors on the Financial Results for the fourth quarter and year ended March 31, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
27 May - Submission of Audio recordings of conference call to discuss the Audited Financial Results for the fourth quarter and financial year ended 31st March, 2024.
Concalls
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
Product Portfolio
A) Contrast media intermediates (70.5% of FY23 revenue)[1]
Contrast media are agents used in medical imaging to enhance visibility of body tissues under X-rays, computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound.